Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
for entities : Novo nordisk a::S save search
Awiqli® (once-weekly basal insulin icodec) recommended for approval for the treatment of diabetes by the European regulatory authorities
Published: 2024-03-21 (Crawled : 16:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -1.04%
H: 1.6%
C: 0.64%
awiqli approval treatment diabetes insulin
Novo Holdings reports Total Income and Investment Returns of DKK 31 billion (€4.2 billion) for 2023. Total Assets grow by 38% to DKK 1,114 billion (€149 billion)
Published: 2024-03-12 (Crawled : 07:00) - prnewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 0.27%
H: 2.67%
C: 2.67%
total
Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease
Published: 2024-03-08 (Crawled : 19:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
| Email alert
Add to watchlist
wegovy obesity disease approved risk cardiovascular
Insulin Pen Global Market Outlook Report 2024-2028: Current Market Size and Revenue Growth Prospects for Insulin Pens, with Market Share Analysis by Type, Onset Time, End User and Geographical Region
Published: 2024-02-23 (Crawled : 17:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.37%
H: 0.58%
C: 0.58%
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 0.0%
H: 1.93%
C: 1.27%
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.68%
H: 0.4%
C: -0.18%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.89%
H: 0.4%
C: 0.17%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.97%
H: 0.0%
C: 0.0%
report revenue global insulin growth market
Notice for the Annual General Meeting of Novo Nordisk A/S
Published: 2024-02-21 (Crawled : 14:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -2.02%
H: 1.67%
C: 1.62%
meeting
Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases
Published: 2024-01-04 (Crawled : 11:00) - globenewswire.com
OMGA | $2.4 -0.83% -0.83% 400K
|
|
| O: 92.31%
H: 20.0%
C: 1.24%
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 1.44%
H: 3.68%
C: 2.4%
treatment research therapeutics
Nalu Medical, Inc. Announces $65 Million Equity Financing to Advance Treatment for Chronic Neuropathic Pain
Published: 2024-01-03 (Crawled : 17:00) - biospace.com/
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.06%
H: 1.75%
C: 1.54%
million treatment
Biologics Global Market Forecast Report 2024-2034 - Challenges Posed by Patent Expiration for Biologics
Published: 2023-12-22 (Crawled : 17:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 3.66%
H: 0.0%
C: -0.12%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 3.33%
H: 0.0%
C: -2.93%
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.31%
H: 0.39%
C: -0.44%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 1.09%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.18%
H: 0.5%
C: -0.46%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.78%
H: 5.15%
C: 2.81%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.58%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 0.52%
H: 0.58%
C: 0.05%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.34%
H: 1.02%
C: 0.59%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.57%
H: 1.36%
C: 1.04%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.06%
H: 0.18%
C: -1.06%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.24%
H: 2.03%
C: 1.49%
patent report global market
Addressing the Global HIV Challenge: Market for Diagnostics and Therapeutics Plays a Crucial Role in Combating HIV/AIDS
Published: 2023-11-03 (Crawled : 17:00) - prnewswire.com
TRUMF | $16.928 -17.59% 1.9K
|
Health Technology
|
| O: -0.28%
H: 4.55%
C: 0.01%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.79%
H: 0.0%
C: 0.0%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.88%
H: 3.51%
C: 2.73%
TRUMY | $16.507 0.79% 34K
|
Manufacturing
|
| O: 3.89%
H: 0.0%
C: -1.74%
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: 2.32%
H: 0.0%
C: 0.0%
QGEN | $40.0 1.34% 0.0% 1.1M
|
Health Technology
|
| O: 2.12%
H: 1.06%
C: 0.51%
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -2.23%
H: 0.16%
C: -0.52%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -1.4%
H: 0.42%
C: 0.0%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 2.15%
H: 0.0%
C: 0.0%
BDX | $234.12 0.42% 0.0% 1.3M
|
Health Technology
|
| O: 1.1%
H: 0.33%
C: 0.07%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -3.04%
H: 0.0%
C: 0.0%
QGEN | $40.0 1.34% 0.0% 1.1M
|
Health Technology
|
| O: 2.12%
H: 1.06%
C: 0.51%
global hiv diagnostics therapeutics market
Global Generic Drugs Business Analysis Report 2023-2030: Small-molecule Generic Drugs Account for a Lion's Share, Biosimilars Exhibit Fastest Growth
Published: 2023-10-23 (Crawled : 19:00) - prnewswire.com
ENDPQ | $0.0006 -50.0% 3.4K
|
n/a
|
| O: -44.44%
H: 60.0%
C: -20.0%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 1.37%
H: 1.36%
C: 1.36%
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 0.45%
H: 2.46%
C: 1.67%
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.79%
H: 1.41%
C: 1.21%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.84%
H: 0.0%
C: 0.0%
BAX | $39.47 -0.45% 0.0% 2.8M
|
Health Technology
|
| O: 0.2%
H: 0.9%
C: -1.05%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -1.82%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.77%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.38%
H: 2.31%
C: 2.02%
report business global growth
Novo Nordisk to acquire ocedurenone for uncontrolled hypertension from KBP Biosciences
Published: 2023-10-16 (Crawled : 11:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.84%
H: 0.19%
C: -0.13%
acquire hypertension
Novo Nordisk raises sales and operating profit outlook for 2023
Published: 2023-10-13 (Crawled : 13:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 1.41%
H: 2.37%
C: 0.54%
sales
FDA approves Rivfloza™ for children ≥9 years old and adults living with primary hyperoxaluria type 1 (PH1), a rare genetic condition
Published: 2023-10-02 (Crawled : 17:00) - biospace.com/
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.85%
H: 3.13%
C: 1.81%
fda rare children genetic living
Acesion Pharma Closes Oversubscribed €45M Series B Financing Round to Advance Development of Novel Therapy for Atrial Fibrillation
Published: 2023-09-26 (Crawled : 06:00) - prnewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 1.81%
H: 0.2%
C: -1.07%
pharma series therapy
Valo Health and Novo Nordisk to collaborate to discover and develop novel treatments for cardiometabolic diseases using human data and artificial intelligence
Published: 2023-09-25 (Crawled : 12:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.44%
H: 0.33%
C: 0.25%
health
Aspen announces contract manufacturing agreement to initiate local production of Human Insulin for Novo Nordisk at its Gqeberha based sterile manufacturing facility
Published: 2023-09-19 (Crawled : 17:00) - aspenpharma.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.56%
H: 1.1%
C: 0.8%
contract agreement insulin
Novo Nordisk conducts a two-for-one stock split
Published: 2023-09-13 (Crawled : 06:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -2.21%
H: 1.23%
C: 0.11%
Global Oral Proteins and Peptides Market Valued at $1.57 Billion in 2022, Driven by Rising Demand for Oral Treatments
Published: 2023-09-12 (Crawled : 00:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 0.89%
H: 0.37%
C: -2.49%
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -2.21%
H: 1.23%
C: 0.11%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.22%
H: 0.33%
C: -1.1%
global market
Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism
Published: 2023-08-30 (Crawled : 06:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.72%
H: 0.36%
C: -0.49%
fda pharma review designation
Innovations and Collaborations Offer New Avenues for Growth in the Global Antiviral Drug Market to 2028
Published: 2023-08-30 (Crawled : 01:00) - prnewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.72%
H: 0.36%
C: -0.49%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.56%
H: 0.0%
C: 0.0%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 0.73%
H: 0.96%
C: 0.32%
drug antiviral global growth market
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.